619.541.6609
We are available 24/7
Olympus duodenoscope litigation has not produced a global settlement program or a federal MDL with a published compensation matrix.
Most cases have been resolved individually, with settlement terms kept confidential under agreement. That makes it difficult to estimate what any specific claim might be worth, but the publicly available verdicts and the factors courts use to evaluate these cases offer a working framework for what compensation could look like.
Only a small number of Olympus endoscope cases have produced publicly reported outcomes. The most significant is the 2017 jury verdict in King County Superior Court in Washington, where a jury awarded $6.6 million in damages arising from a deadly CRE outbreak at Virginia Mason Medical Center. Patient Richard Bigler died after undergoing an ERCP procedure involving an Olympus TJF-Q180V duodenoscope contaminated with drug-resistant bacteria. The jury determined Olympus bore primary responsibility for the outbreak and ordered the hospital to pay an additional $1 million to the Bigler family.
Following that trial, Olympus settled wrongful death lawsuits brought by the families of Theresa Bigler and Deborah Shawver, both of whom alleged their husbands died after contracting CRE infections linked to Olympus duodenoscopes. Financial terms in both cases were not publicly disclosed. An earlier wrongful death lawsuit involving Bill Warner, who died in 2013 after developing a CRE infection allegedly linked to an Olympus scope, also ended in a confidential settlement before trial.
Legal publications indicate Olympus reached numerous additional confidential settlements with patients and families during the first wave of litigation involving CRE infections, sepsis, wrongful death, permanent injury, and extended hospitalization. Because no MDL exists and cases are negotiated individually, no publicly available average settlement figure exists for this litigation.
In December 2018, Olympus Medical Systems Corporation pleaded guilty to federal charges related to failing to report adverse events connected to contaminated duodenoscopes and agreed to pay $85 million in criminal fines and forfeiture. That resolution did not compensate injured patients directly but is regularly cited in civil litigation as evidence of the company's conduct.
Because compensation in this litigation is evaluated case by case rather than through a standardized matrix, the starting point for valuation is what the infection actually did to the patient. A case involving a drug-resistant superbug infection that required weeks of intensive care, caused permanent organ damage, or resulted in death carries significantly different weight than a case involving a shorter hospitalization with full recovery. Courts and defendants evaluate how painful the injury was, how expensive it was to treat, and whether the patient will face ongoing medical needs as a result.
Product liability damages are not limited to medical bills. The damage calculation also takes into account:
These effects are much better documented in medical records, employment records and doctor's notes, making the case for damages much stronger.
The third variable is how courts and juries evaluate Olympus's conduct. Plaintiffs in active cases allege Olympus knew its reprocessing instructions were insufficient to eliminate contamination, continued distributing affected devices while adverse-event reports went unfiled with the FDA, and delayed design changes that would have reduced infection risk. A U.S. Senate investigation concluded Olympus had contamination information before U.S. hospitals and regulators were fully informed.
In jurisdictions where courts determine that Olympus engaged in gross negligence or reckless disregard for patient safety, courts may award punitive damages in addition to compensatory damages. The $6.6 million Washington verdict and the $85 million federal criminal resolution both reflect findings that the company's conduct went beyond ordinary product failure.
Compensation in Olympus scope litigation depends on the specific facts of each case, the severity of the injury, and the strength of the medical documentation connecting the infection to the procedure. Our team has spent more than 35 years helping patients evaluate whether they have a viable product liability claim and connecting those who qualify with attorneys prepared to represent them. If you or a family member was harmed by a contaminated Olympus scope, reach out today for a free and confidential case evaluation.